DDInter221 DDInter899
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Boceprevir {u} (Compound) resembles {v} (Compound) Telaprevir
Boceprevir {u} (Compound) binds {v} (Gene) CMA1
Boceprevir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Boceprevir {u} (Compound) causes {v} (Side Effect) Sepsis
Boceprevir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Boceprevir {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Boceprevir {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Boceprevir (Compound) resembles Telaprevir (Compound)
Boceprevir (Compound) binds CMA1 (Gene)
Boceprevir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Boceprevir (Compound) causes Sepsis (Side Effect)
Boceprevir may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Boceprevir may lead to a major life threatening interaction when taken with Glasdegib
Boceprevir may lead to a major life threatening interaction when taken with Apixaban